FDA awarded Tempus breakthrough designation status for an AI algorithm to predict AFib from a normal ECG. Tempus also received FDA approval for ECG-Low EF software to identify patients with low left ventricular ejection fraction. The company works in regulated clinical settings, balancing R&D speed with validation, and supports FDA partial 510(k) exemption proposals for AI medical devices.
All receipts on Tempus
Tempus
Lab workers at Tempus pushed for unionization citing workplace safety concerns and stagnant wages. Crain's Chicago Business reported employees want more say in workplace safety and better pay. Tempus went public in June 2024 at a $6.1B valuation and has been named to Forbes AI 50 list for its precision medicine work.
Share this receipt
Posts with the receipt card attached.
Post this receiptDownload card
Tempus — Worker Treatment: MIXED Lab workers at Tempus pushed for unionization citing workplace safety concerns and stagnant wages. Crain's Chicago Business reported employees want more say in workplace safety … https://reciepts.tech/stance/1352